Substance P antagonist MK-869 (L-754,030) will be studied in a Phase III clinical trial for prevention of chemotherapy-induced emesis to begin this year, based on a Phase II trial published in the Jan. 21 New England Journal of Medicine ("The Pink Sheet" May 25, 1998, p. 25). A recent Phase II study in depression was "not definitive due to a high placebo response rate" but suggested activity at one dose, Merck said. The company is evaluating the development of MK-869 for depression and is commencing a Phase II trial for that indication with a backup Substance P antagonist
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.
Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.